Effects of aripiprazole vs. haloperidol on brain activity in healthy volunteers

[1]  C. Pariante,et al.  Effects of aripiprazole and haloperidol on neural activation during the n-back in healthy individuals: A functional MRI study , 2016, Schizophrenia Research.

[2]  O. Andreassen,et al.  Negative symptoms in schizophrenia are associated with aberrant striato-cortical connectivity in a rewarded perceptual decision-making task , 2015, NeuroImage: Clinical.

[3]  Chris J. Martin,et al.  A systematic review of physiological methods in rodent pharmacological MRI studies , 2015, Psychopharmacology.

[4]  L. Farde,et al.  Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia , 2014, Schizophrenia Research.

[5]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[6]  R. Murray,et al.  Schizophrenia: an integrated sociodevelopmental-cognitive model , 2014, The Lancet.

[7]  J. van os,et al.  Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis , 2014, PloS one.

[8]  L. Pani,et al.  The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review , 2014, CNS Drugs.

[9]  Daniel R. Weinberger,et al.  The global cognitive impairment in schizophrenia: Consistent over decades and around the world , 2013, Schizophrenia Research.

[10]  Dimitris Mavridis,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[11]  Bruce R. Rosen,et al.  A receptor-based model for dopamine-induced fMRI signal , 2013, NeuroImage.

[12]  D. Rujescu,et al.  Improved Detection of Common Variants Associated with Schizophrenia and Bipolar Disorder Using Pleiotropy-Informed Conditional False Discovery Rate , 2013, PLoS genetics.

[13]  H. Meltzer.  Update on typical and atypical antipsychotic drugs. , 2013, Annual review of medicine.

[14]  R. Murray,et al.  Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. , 2012, The American journal of psychiatry.

[15]  H. Flor,et al.  Activation of the ventral striatum during aversive contextual conditioning in humans , 2012, Biological Psychology.

[16]  Sara E. Morrison,et al.  Representations of appetitive and aversive information in the primate orbitofrontal cortex , 2011, Annals of the New York Academy of Sciences.

[17]  S. Kapur,et al.  Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. , 2011, The international journal of neuropsychopharmacology.

[18]  Pablo V Gejman,et al.  Genetics of schizophrenia: new findings and challenges. , 2011, Annual review of genomics and human genetics.

[19]  E. Bullmore,et al.  The Diagnosis of Psychosis , 2011 .

[20]  Y. Inoue,et al.  An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  Edith Pomarol-Clotet,et al.  Overall brain connectivity maps show cortico‐subcortical abnormalities in schizophrenia , 2010, Human brain mapping.

[22]  Ruben C. Gur,et al.  PAGES_DCNS 46_5.qxd:DCNS#45 , 2010 .

[23]  R. Murray,et al.  Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines , 2010, Schizophrenia Research.

[24]  E. Bullmore,et al.  Behavioral / Systems / Cognitive Functional Connectivity and Brain Networks in Schizophrenia , 2010 .

[25]  Anders M. Dale,et al.  CORTICAL THICKNESS AND SUBCORTICAL VOLUMES IN SCHIZOPHRENIA AND BIPOLAR DISORDER , 2010, Schizophrenia Research.

[26]  G. Juckel,et al.  Switching schizophrenia patients from typical neuroleptics to aripiprazole: Effects on working memory dependent functional activation , 2010, Schizophrenia Research.

[27]  A. Heinz,et al.  Dopaminergic dysfunction in schizophrenia: salience attribution revisited. , 2010, Schizophrenia bulletin.

[28]  A. Mortimer,et al.  Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. , 2010, Clinical schizophrenia & related psychoses.

[29]  Eleanor H. Simpson,et al.  A Possible Role for the Striatum in the Pathogenesis of the Cognitive Symptoms of Schizophrenia , 2010, Neuron.

[30]  S. Kapur,et al.  Dopamine-induced changes in neural network patterns supporting aversive conditioning , 2010, Brain Research.

[31]  H. Walter,et al.  Temporally anticorrelated brain networks during working memory performance reveal aberrant prefrontal and hippocampal connectivity in patients with schizophrenia , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[32]  Frank Baumann,et al.  The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory , 2009, Psychopharmacology.

[33]  M. Minzenberg,et al.  Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. , 2009, Archives of general psychiatry.

[34]  Joseph E LeDoux,et al.  Avoiding Negative Outcomes: Tracking the Mechanisms of Avoidance Learning in Humans During Fear Conditioning , 2009, Front. Behav. Neurosci..

[35]  J. Tsien,et al.  Memory and the NMDA receptors. , 2009, The New England journal of medicine.

[36]  Jianxin Shi,et al.  Common variants on chromosome 6p22.1 are associated with schizophrenia , 2009, Nature.

[37]  J. Feldon,et al.  Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. , 2009, The international journal of neuropsychopharmacology.

[38]  S. Kapur,et al.  The dopamine hypothesis of schizophrenia: version III--the final common pathway. , 2009, Schizophrenia bulletin.

[39]  A. Carlsson,et al.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.

[40]  P. Tyrer,et al.  The spurious advance of antipsychotic drug therapy , 2009, The Lancet.

[41]  H. Heinze,et al.  Mesolimbic Functional Magnetic Resonance Imaging Activations during Reward Anticipation Correlate with Reward-Related Ventral Striatal Dopamine Release , 2008, The Journal of Neuroscience.

[42]  M. Delgado,et al.  The role of the striatum in aversive learning and aversive prediction errors , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.

[43]  Ole A. Andreassen,et al.  Association between a disrupted-in-schizophrenia 1 (DISC1) single nucleotide polymorphism and schizophrenia in a combined Scandinavian case–control sample , 2008, Schizophrenia Research.

[44]  J. McGrath,et al.  Schizophrenia: a concise overview of incidence, prevalence, and mortality. , 2008, Epidemiologic reviews.

[45]  E. Rolls,et al.  The orbitofrontal cortex and beyond: From affect to decision-making , 2008, Progress in Neurobiology.

[46]  J. Newcomer,et al.  Addressing cardiometabolic risk during treatment with antipsychotic medications , 2008, Current opinion in psychiatry.

[47]  E. Kandel,et al.  Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning , 2008, Proceedings of the National Academy of Sciences.

[48]  Ole A. Andreassen,et al.  Association analysis of schizophrenia on 18 genes involved in neuronal migration: MDGA1 as a new susceptibility gene , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[49]  Thomas W. Mühleisen,et al.  Large recurrent microdeletions associated with schizophrenia , 2008, Nature.

[50]  David Borsook,et al.  A ‘BOLD’ experiment in defining the utility of fMRI in drug development , 2008, NeuroImage.

[51]  E. Bullmore,et al.  The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. , 2008, The American journal of psychiatry.

[52]  Andreas Heinz,et al.  Switching schizophrenia patients from typical neuroleptics to olanzapine: Effects on BOLD response during attention and working memory , 2008, European Neuropsychopharmacology.

[53]  Henry A. Nasrallah,et al.  Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology , 2008, Schizophrenia Research.

[54]  John P A Ioannidis,et al.  Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database , 2008, Nature Genetics.

[55]  N. Logothetis.  What we can do and what we cannot do with fMRI , 2008, Nature.

[56]  L. Hranov,et al.  Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.

[57]  Michael E Talkowski,et al.  A network of dopaminergic gene variations implicated as risk factors for schizophrenia. , 2008, Human molecular genetics.

[58]  S. Kapur,et al.  The Formation of Abnormal Associations in Schizophrenia: Neural and Behavioral Evidence , 2008, Neuropsychopharmacology.

[59]  Ming Li,et al.  Amphetamine selectively enhances avoidance responding to a less salient stimulus in rats , 2008, Journal of Neural Transmission.

[60]  Michael Moutoussis,et al.  Persecutory delusions and the conditioned avoidance paradigm: Towards an integration of the psychology and biology of paranoia , 2007, Cognitive neuropsychiatry.

[61]  S. Ikemoto.  Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens–olfactory tubercle complex , 2007, Brain Research Reviews.

[62]  S. Kapur,et al.  Temporal Difference Modeling of the Blood-Oxygen Level Dependent Response During Aversive Conditioning in Humans: Effects of Dopaminergic Modulation , 2007, Biological Psychiatry.

[63]  W. Eaton,et al.  Epidemiology of schizophrenia: review of findings and myths. , 2007, The Psychiatric clinics of North America.

[64]  T. Ban.  Fifty years chlorpromazine: a historical perspective , 2007, Neuropsychiatric disease and treatment.

[65]  Peter B. Jones,et al.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review , 2007, The Lancet.

[66]  D. Goff,et al.  Inflammation and schizophrenia , 2007, Expert review of neurotherapeutics.

[67]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[68]  D. S. Zahm,et al.  Glutamatergic Afferents of the Ventral Tegmental Area in the Rat , 2007, The Journal of Neuroscience.

[69]  E. Cantor-Graae.  The Contribution of Social Factors to the Development of Schizophrenia: A Review of Recent Findings , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[70]  S. Kapur,et al.  Separate brain regions code for salience vs. valence during reward prediction in humans , 2007, Human brain mapping.

[71]  S. Nicola.  The nucleus accumbens as part of a basal ganglia action selection circuit , 2007, Psychopharmacology.

[72]  K. Berridge.  The debate over dopamine’s role in reward: the case for incentive salience , 2007, Psychopharmacology.

[73]  T. Robbins,et al.  Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls , 2007, Molecular Psychiatry.

[74]  M. Mintun,et al.  Brain work and brain imaging. , 2006, Annual review of neuroscience.

[75]  Peter B. Jones,et al.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.

[76]  Thomas A. Ban,et al.  The role of serendipity in drug discovery , 2006, Dialogues in clinical neuroscience.

[77]  G. Remington,et al.  Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood , 2006, Schizophrenia Research.

[78]  Michael F. Green,et al.  The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine , 2006, Psychopharmacology.

[79]  J. Coyle,et al.  Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis , 2006, Cellular and Molecular Neurobiology.

[80]  Karl J. Friston,et al.  Synaptic Plasticity and Dysconnection in Schizophrenia , 2006, Biological Psychiatry.

[81]  Hans-Georg Buchholz,et al.  Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge , 2006, NeuroImage.

[82]  J. Lieberman,et al.  Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. , 2006, The American journal of psychiatry.

[83]  E. Kandel,et al.  Transient and Selective Overexpression of Dopamine D2 Receptors in the Striatum Causes Persistent Abnormalities in Prefrontal Cortex Functioning , 2006, Neuron.

[84]  Arno Villringer,et al.  Dysfunction of ventral striatal reward prediction in schizophrenia , 2006, NeuroImage.

[85]  M. Lepage,et al.  Episodic memory-related activation in schizophrenia: meta-analysis , 2005, British Journal of Psychiatry.

[86]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[87]  Herbert Y Meltzer,et al.  A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. , 2005, The international journal of neuropsychopharmacology.

[88]  M. Egan,et al.  Effect of Catechol-O-Methyltransferase val158met Genotype on Attentional Control , 2005, The Journal of Neuroscience.

[89]  J. McGrath,et al.  A Systematic Review of the Prevalence of Schizophrenia , 2005, PLoS medicine.

[90]  S. Kapur,et al.  Evidence for onset of antipsychotic effects within the first 24 hours of treatment. , 2005, The American journal of psychiatry.

[91]  D. Glahn,et al.  Beyond hypofrontality: A quantitative meta‐analysis of functional neuroimaging studies of working memory in schizophrenia , 2005, Human brain mapping.

[92]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[93]  S. Lawrie,et al.  Cannabis as a risk factor for psychosis: systematic review , 2005, Journal of psychopharmacology.

[94]  J. Kemp,et al.  Ionotropic and metabotropic glutamate receptor structure and pharmacology , 2005, Psychopharmacology.

[95]  Andreas Heinz,et al.  Catechol-O-Methyltransferase val158met Genotype Affects Processing of Emotional Stimuli in the Amygdala and Prefrontal Cortex , 2005, The Journal of Neuroscience.

[96]  I. Nimmo-Smith,et al.  Hypofrontality in schizophrenia: a meta‐analysis of functional imaging studies , 2004, Acta psychiatrica Scandinavica.

[97]  Elena Antonova,et al.  The relationship between brain structure and neurocognition in schizophrenia: a selective review , 2004, Schizophrenia Research.

[98]  Morten L Kringelbach,et al.  Methamphetamine Activates Reward Circuitry in Drug Naïve Human Subjects , 2004, Neuropsychopharmacology.

[99]  P. Fletcher,et al.  Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases , 2004, Pharmacology Biochemistry and Behavior.

[100]  Brian Knutson,et al.  Amphetamine Modulates Human Incentive Processing , 2004, Neuron.

[101]  E. Bullmore,et al.  Human pharmacological MRI. , 2004, Trends in pharmacological sciences.

[102]  S. Kapur,et al.  A Model of Antipsychotic Action in Conditioned Avoidance: A Computational Approach , 2004, Neuropsychopharmacology.

[103]  Patricia S. Goldman-Rakic,et al.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction , 2004, Psychopharmacology.

[104]  E. Rolls,et al.  The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology , 2004, Progress in Neurobiology.

[105]  Jens C. Pruessner,et al.  Dopamine Release in Response to a Psychological Stress in Humans and Its Relationship to Early Life Maternal Care: A Positron Emission Tomography Study Using [11C]Raclopride , 2004, The Journal of Neuroscience.

[106]  Lars Kai Hansen,et al.  Finding related functional neuroimaging volumes , 2004, Artif. Intell. Medicine.

[107]  R. Carnahan,et al.  Aripiprazole, a Novel Atypical Antipsychotic Drug , 2004, Pharmacotherapy.

[108]  A. Lawrence,et al.  Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. , 2004, Archives of general psychiatry.

[109]  S. Kapur,et al.  Direct Activation of the Ventral Striatum in Anticipation of Aversive Stimuli , 2003, Neuron.

[110]  M. D’Esposito,et al.  Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging , 2003, Nature Reviews Neuroscience.

[111]  A. Belger,et al.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development , 2003, Psychopharmacology.

[112]  E T Bullmore,et al.  Dopaminergic drug effects on physiological connectivity in a human cortico-striato-thalamic system. , 2003, Brain : a journal of neurology.

[113]  Paul J. Laurienti,et al.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets , 2003, NeuroImage.

[114]  J. Gorman,et al.  Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications , 2003, Psychopharmacology.

[115]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[116]  M. Egan,et al.  Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Dieter F. Braus,et al.  Haloperidol challenge in healthy male humans: a functional magnetic resonance imaging study , 2003, Neuroscience Letters.

[118]  D. Manoach.  Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings , 2003, Schizophrenia Research.

[119]  R. Heinrichs,et al.  Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis , 2003, Psychiatry Research: Neuroimaging.

[120]  W. Schultz.  Getting Formal with Dopamine and Reward , 2002, Neuron.

[121]  J. Kane,et al.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. , 2002, The Journal of clinical psychiatry.

[122]  Gerhard Gründer,et al.  Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride , 2002, Neuropsychopharmacology.

[123]  Kevin D Burris,et al.  Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors , 2002, Journal of Pharmacology and Experimental Therapeutics.

[124]  Peter B. Jones,et al.  Obstetric complications and schizophrenia: historical and meta-analytic review. , 2002, The American journal of psychiatry.

[125]  J. Mann,et al.  Central Nervous System Monoamine Correlates of Social Dominance in Cynomolgus Monkeys (Macaca fascicularis) , 2002, Neuropsychopharmacology.

[126]  A. Meyer-Lindenberg,et al.  Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia , 2002, Nature Neuroscience.

[127]  M. Nader,et al.  Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration , 2002, Nature Neuroscience.

[128]  Shitij Kapur,et al.  Dopamine D2 Receptor Occupancy Is a Common Mechanism Underlying Animal Models of Antipsychotics and Their Clinical Effects , 2001, Neuropsychopharmacology.

[129]  J. Kane.  Extrapyramidal side effects are unacceptable , 2001, European Neuropsychopharmacology.

[130]  S. Heckers,et al.  Neuroimaging studies of the hippocampus in schizophrenia , 2001, Hippocampus.

[131]  E. Walker,et al.  Dopamine receptors in the brains of schizophrenia patients: a meta‐analysis of the findings , 2001, Behavioural pharmacology.

[132]  F. Benes,et al.  GABAergic Interneurons: Implications for Understanding Schizophrenia and Bipolar Disorder , 2001, Neuropsychopharmacology.

[133]  E A Stein,et al.  fMRI: a new tool for the in vivo localization of drug actions in the brain. , 2001, Journal of analytical toxicology.

[134]  R. Straub,et al.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[135]  R. McCarley,et al.  A review of MRI findings in schizophrenia , 2001, Schizophrenia Research.

[136]  H. Holcomb,et al.  Neural networks: neural systems vi: basal ganglia. , 2001, The American journal of psychiatry.

[137]  S. Vinogradov,et al.  The functional relevance of affect recognition errors in schizophrenia , 2000, Journal of the International Neuropsychological Society.

[138]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[139]  J. Miñarro,et al.  Different inhibition of conditioned avoidance response by clozapine and DA D1 and D2 antagonists in male mice. , 2000, Behavioral neuroscience.

[140]  I. Gottesman,et al.  Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. , 2000, American journal of medical genetics.

[141]  P. Hicks,et al.  The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? , 1999, Neuroscience & Biobehavioral Reviews.

[142]  A. Malhotra,et al.  Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. , 1999, The American journal of psychiatry.

[143]  J. O'hanlon,et al.  Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. , 1999, Journal of clinical psychopharmacology.

[144]  R. Roth,et al.  The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.

[145]  Tamara Hershey,et al.  Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.

[146]  K. Berridge,et al.  What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? , 1998, Brain Research Reviews.

[147]  M. Laruelle.  Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[148]  K. Miczek,et al.  Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study , 1996, Brain Research.

[149]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[150]  S. Morita,et al.  7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. , 1995, The Journal of pharmacology and experimental therapeutics.

[151]  J L Lancaster,et al.  Neuroscience on the net. , 1994, Science.

[152]  D. Hoyer,et al.  Partial agonists, full agonists, antagonists: dilemmas of definition. , 1993, Trends in pharmacological sciences.

[153]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[154]  W. Schultz,et al.  Neuronal activity in monkey ventral striatum related to the expectation of reward , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[155]  P. Seeman.  Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[156]  S. Ahlénius,et al.  Suppression of conditioned avoidance behavior by the local application of (−)sulpiride into the ventral, but not the dorsal, striatum of the rat , 1990, Biological Psychiatry.

[157]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[158]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[159]  D. Weinberger,et al.  Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. , 1988, Archives of general psychiatry.

[160]  T. Shallice.  Specific impairments of planning. , 1982, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[161]  G. Radda,et al.  Oxygenation dependence of the transverse relaxation time of water protons in whole blood at high field. , 1982, Biochimica et biophysica acta.

[162]  M. Olkinuora,et al.  Agranulocytosis during treatment with clozapine , 1977, European Journal of Clinical Pharmacology.

[163]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[164]  P. Seeman,et al.  Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.

[165]  J. Davies,et al.  The effect of anti-Parkinsonian drugs on haloperidol-induced inhibition of the conditioned-avoidance response in rats. , 1973, Neuropharmacology.

[166]  J. Gaddum,et al.  Drugs which antagonize 5-hydroxytryptamine. , 1954, British journal of pharmacology and chemotherapy.

[167]  M. Adler.  Diagnostic and Statistical Manual of Mental Disorders, 4th Edition , 2016 .

[168]  N. Woodward,et al.  Resting-state networks in schizophrenia. , 2012, Current topics in medicinal chemistry.

[169]  M. Wadenberg.  Conditioned avoidance response in the development of new antipsychotics. , 2010, Current pharmaceutical design.

[170]  H. Meltzer,et al.  In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. , 2008, Progress in brain research.

[171]  M. Schwarz,et al.  The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. , 2007, Journal of neural transmission. Supplementum.

[172]  R. Narendran,et al.  Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. , 2005, Clinical therapeutics.

[173]  Dennis Velakoulis,et al.  Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. , 2005, Schizophrenia bulletin.

[174]  E. Cantor-Graae,et al.  Schizophrenia and migration: a meta-analysis and review. , 2005, The American journal of psychiatry.

[175]  Lydia Krabbendam,et al.  Schizophrenia and urbanicity: a major environmental influence--conditional on genetic risk. , 2005, Schizophrenia bulletin.

[176]  C. Perry,et al.  Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. , 2004, Drugs.

[177]  H. Kornhuber,et al.  Reduction of cerebrospinal fluid glutamic acid in huntington's chorea and in schizophrenic patients , 2004, Archiv für Psychiatrie und Nervenkrankheiten.

[178]  Alan I Green,et al.  Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). , 2003, Archives of general psychiatry.

[179]  S. Kapur.  Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. , 2003, The American journal of psychiatry.

[180]  H. Meltzer,et al.  An atypical compound by any other name is still a.... , 2000, Psychopharmacology.

[181]  J. Lieberman,et al.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. , 1999, Schizophrenia bulletin.

[182]  S. R. Nash,et al.  Dopamine receptors: from structure to function. , 1998, Physiological reviews.

[183]  G. Dunbar,et al.  The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI , 1997, European Psychiatry.

[184]  S. Haber,et al.  The primate substantia nigra and VTA: integrative circuitry and function. , 1997, Critical reviews in neurobiology.

[185]  Karl J. Friston,et al.  Schizophrenia: a disconnection syndrome? , 1995, Clinical neuroscience.

[186]  J. Davis,et al.  Important issues in the drug treatment of schizophrenia. , 1980, Schizophrenia bulletin.